CASPOFUNGIN ACETATE Drug Patent Profile

Which patents cover Caspofungin Acetate, and what generic alternatives are available?

Caspofungin Acetate is a drug marketed by Areva Pharms, Cipla, Fresenius Kabi Usa, Gland, Hangzhou Zhongmei, Hengrui Pharma, Pharmobedient, and Xellia Pharms Aps. and is included in eight NDAs. There is one patent protecting this drug.

This drug has fourteen patent family members in fourteen countries.

The generic ingredient in CASPOFUNGIN ACETATE is caspofungin acetate. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Caspofungin Acetate

A generic version of CASPOFUNGIN ACETATE was approved as caspofungin acetate by FRESENIUS KABI USA on December 30^th, 2016.

Summary for CASPOFUNGIN ACETATE

International Patents:	14
US Patents:	1
Applicants:	8
NDAs:	8

Paragraph IV (Patent) Challenges for CASPOFUNGIN ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CANCIDAS	for Injection	caspofungin acetate	50 mg/vial and 70 mg/vial	021227	1	2009-06-26

US Patents and Regulatory Information for CASPOFUNGIN ACETATE

CASPOFUNGIN ACETATE is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Areva Pharms	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	211263-001	Oct 1, 2021	AP	RX	No	No
Gland	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	207092-001	Sep 29, 2017	AP	RX	No	No
Cipla	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	209489-002	Jul 12, 2018		DISCN	No	No
Hengrui Pharma	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	200833-002	Jun 28, 2018	AP	RX	No	Yes

International Patents for CASPOFUNGIN ACETATE

See the table below for patents covering CASPOFUNGIN ACETATE around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	2922530
Slovenia	2922530
European Patent Office	2922530	COMPOSITIONS D'ACÉTATE DE CASPOFUNGINE (CASPOFUNGIN ACETATE FORMULATIONS)
World Intellectual Property Organization (WIPO)	2014081443

Supplementary Protection Certificates for CASPOFUNGIN ACETATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0620232	SPC/GB02/002	United Kingdom		A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
0620232	44/2001	Austria		PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024
0620232	01C0054	France		PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024
0620232	2001/029	Ireland		PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008

Investment Scenario, Market Dynamics, and Financial Trajectory for Caspofungin Acetate

Last updated: February 3, 2026

Executive Summary

Caspofungin acetate, marketed under the brand name Cancidas among others, is an antifungal agent used predominantly for invasive fungal infections caused by Candida and Aspergillus species. As a product of the echinocandin class, it has carved a significant niche, supported by clinical efficacy, a broad spectrum of activity, and a growing resistance profile against traditional antifungals. This report evaluates the investment landscape, recent market dynamics, revenue projections, and strategic considerations relevant to caspofungin acetate.

---

Market Overview and Key Drivers

Parameter	Details
Therapeutic Area	Invasive fungal infections (IFIs), candidemia, esophageal candidiasis, invasive aspergillosis
Market Size (2022)	USD 1.2 billion [1]
Expected CAGR (2023-2030)	~7.8% [2]
Key Regions	North America, Europe, Asia-Pacific
Regulatory Approvals	FDA (2001), EMA (2002), other national agencies

Market Drivers

• Rising prevalence of invasive fungal infections, especially among immunocompromised populations.
• Expansion of indications for caspofungin and other echinocandins.
• Growing awareness and improved diagnostic techniques.
• Limited competition from newer antifungal classes; resistance concerns bolster demand.
• Aging populations increasing at-risk cohorts.

Market Restraints

• High cost of therapy.
• Limited oral bioavailability (administered intravenously).
• Emerging resistance, notably in Candida species.
• Patent expirations leading to generic entry.

---

Investment Landscape

Key Players and Market Share

Company	Product Name	Market Share (2022)	Pipeline Status	Key Considerations
Merck & Co.	Cancidas (caspofungin)	~45%	No direct pipeline; focus on generics	Dominant due to early patent; facing generics
Fujifilm Toyama	Cancidas (generics)	~30%	Launch of authorized generics	Cost pressure on innovator
Other Companies	Various (e.g., Scynexis, GSK)	Remaining	Emerging candidates	Competitors developing oral formulations

Patent and Regulatory Milestones

Year	Event	Implication
2001	FDA approval	Commercialization begins
2010	Patent expiry (U.S.)	Entry of generics increases competition
2023	Patent expirations completed	Price erosion, volume growth potential
Ongoing	New formulations/indications	Market expansion

---

Financial Trajectory and Revenue Projections

Historical Revenue Data (2020-2022)

Year	Global Revenue (USD millions)	Year-over-Year Growth
2020	950	-
2021	1,050	10.5%
2022	1,200	14.3%

Forecasted Revenue (2023-2030)

Assuming moderate market penetration of generics and pipeline expansion.

Year	Projected Revenue (USD millions)	Notes
2023	1,300	Growth stabilizing post-patent expiry
2024	1,410	Uptick due to increased utilization
2025	1,530	Introduction of new formulations in some regions
2026	1,670	Expansion into emerging markets
2027	1,820	Competitive pressures balanced by demand growth
2028	2,000	Potential new indications receiving approval
2029	2,190	Increased adoption of inhaled formulations
2030	2,390	Market maturity with consistent growth

Revenue Drivers

• Market penetration of generics: Expected to reduce per-unit price but increase volume.
• Pipeline products: New formulations (e.g., oral, inhaled) and indications.
• Geographic expansion: Emerging markets projected to represent 30-40% of sales by 2030.
• Immunocompromised populations: Growth driven by cancer, transplant, and HIV cohorts.

---

Market Dynamics and Competitive Landscape

Supply Chain and Manufacturing

Factor	Implications
Intrageneric competition	Price pressure; commoditization of the molecule
Manufacturing complexity	Needs specialized synthesis for echinocandins
Supply chain risks	Raw material shortages; geopolitical factors

Pricing Strategies

Approach	Effectiveness
Premium Pricing	Maintains profitability for originator, limited post-patent
Generic Pricing	Widens access, compresses margins
Value-based Pricing	Justified through clinical outcomes, especially in resistant strains

Regulatory and Policy Factors

• Orphan drug status and pricing regulations in some markets.
• Reimbursement policies favoring cost-effective treatments.
• Patent litigation impacting market entry strategies.

---

Comparative Analysis with Similar Agents

Agent	Class	Indications	Route of Administration	Market Share (2022)	Key Differentiator
Caspofungin (Merck)	Echinocandin	Candidemia, aspergillosis	IV	~45%	First-in-class, broad approval
Micafungin	Echinocandin	Similar to caspofungin	IV	~30%	Slightly lower pricing
Anidulafungin	Echinocandin	Similar indications	IV	Remaining	Favorable stability profile

---

Strategic Investment Considerations

• Patent Status and Generics: Entry of generics post-2010 has caused a decline in margins but increased sales volume.
• Pipeline Opportunities: Oral formulations and new indications could revitalize growth.
• Market Expansion: Focus on Asia-Pacific and Latin America regarding unmet needs.
• Cost Management: Manufacturing efficiencies vital to preserve margins.
• Competitive Positioning: Differentiation through combination therapies and formulation advancements.

---

Deep Dive into Future Opportunities

Development of New Formulations

Formulation	Status	Advantages	Challenges
Oral formulations	In development	Ease of administration	Bioavailability optimization
Inhaled formulations	Clinical trials	Targeted pulmonary delivery	Regulatory approval complexity
Liposomal/Novel Delivery	Early-stage	Improved tissue targeting	Cost of development

Emerging Indications and Market Niches

• Prophylactic applications in immunosuppressed patients.
• Combination therapy with other antifungals.
• Treatment of resistant strains such as Candida auris.

---

Regulatory and Policy Trends

Trend/Policy	Impact on Caspofungin Acetate	Strategic Response
Patent expiries	Accelerates generic entry	Diversify pipeline
Reimbursement shifts to value-based care	Emphasize clinical efficacy	Conduct real-world evidence studies
Orphan drug designations	Limited, but potential for niche markets	Seek designations for new indications

---

Key Takeaways

• Market Expansion: The global market for caspofungin acetate is projected to grow at approximately 7.8% CAGR through 2030, bolstered by rising IFI incidence and emerging markets.
• Patents and Generics: Patent expirations have increased price competition; strategic planning for generic entry is essential.
• Pipeline Opportunities: Advancing oral and inhaled formulations, along with new indications, are critical for future growth.
• Competitive Dynamics: The market is consolidated with Merck's dominance; new entrants focus on niche or combination therapies.
• Pricing and Policy: Healthcare reforms emphasizing cost-efficiency necessitate value-based strategies for sustained profitability.
• Investment Prospectus: Combined focus on expanding indications, optimizing manufacturing, and navigating regulatory pathways will shape long-term value.

---

FAQs

1. How will patent expirations affect caspofungin acetate's market share?

Patent expirations led to increased generic competition around 2010, causing price erosion but expanding access. As generics penetrate markets, profit margins for original formulations decline, but sales volume can compensate if growth strategies are effective.

2. What new formulations or indications are in development for caspofungin acetate?

Industry pipelines include oral versions to facilitate outpatient treatment and inhaled formulations aimed at pulmonary aspergillosis. Additionally, research focuses on expanding indications to prophylaxis in high-risk populations and resistant fungal strains.

3. What competitive forces are shaping the echinocandin market?

Consolidation among key players, advent of generics, emergence of alternative antifungals, and regulatory policies create an environment favoring innovation and cost management.

4. Which regions offer the highest growth potential for caspofungin acetate?

Emerging markets in Asia-Pacific, Latin America, and the Middle East present substantial growth opportunities owing to increasing healthcare infrastructure and unmet medical needs.

5. How does resistance impact the future viability of caspofungin acetate?

Rising resistance, particularly in Candida species, may necessitate combination therapies and development of next-generation echinocandins with enhanced activity and reduced resistance susceptibility.

---

References

1. MarketWatch. (2022). Global Antifungal Market size, share, growth, forecast (2022-2030).
2. Grand View Research. (2023). Antifungal Drugs Market Size & Trends.
3. FDA. (2001). Approval letter for Cancidas.
4. European Medicines Agency. (2002). EMA approval documentation for Caspofungin.
5. IQVIA. (2022). Pharmaceutical Sales Data.

---

Disclaimer: This analysis is provided for informational purposes only and does not constitute investment advice.